Replies to post #216499 on Biotech Values

[DewDiligence]

Is ENTA still a buy?

...if you did not hold any ENTA at this moment, would you buy the stock at the current price point?

Yes; however, if I were buying ENTA de novo it would be a somewhat smaller position than what I currently own (at an average price in the teens).

Mavyret is going to be a big-selling product in the US, EU, and Japan, ensuring ENTA’s profitability for several years to come despite the relatively modest royalty rate ENTA gets from ABBV.

The new 21% US tax rate will considerably boost ENTA's profits insofar as Mavyret royalties are considered US income regardless of the geographic source of ABBV’s in-market sales.

At ENTA’s current valuation, the EDP-305 program in NASH/PBC—and the earlier-stage programs in RSV and HBV—are essentially free.

Despite your skepticism regarding FXR agonists, you should consider EDP-305 on its own merits. I posted some new info about the EDP-305 dosing in #msg-137556634.

[Whalatane]

MYOK. Biotech Jim ..Also listened to web cast
Yes 2018 will be an active yr . Only thing I didn't like is that their reviewing of final trial protocol with the FDA appears to have been pushed back. From memory of 2017 CC's they always said final meeting with FDA by end of 2017 .
They probably needed the low dose data before the final FDA meeting ....and since they will present that data on March 10th at ACC......I'm assuming final FDA meeting any week now .
That should lift the stock ..when the FDA signs off ...as this will be their pivotal ( P 3 ) trial
JMO
Kiwi